A 47-year-old man with acute hepatitis B virus (HBV) infection who had been receiving immunosuppressants after renal transplantation developed progressive liver failure. During the clinical course (approximately 7 months), anti-HBc IgM antibody and HBV-DNApolymerase levels remained high, but the serum alanine aminotransferase (ALT) level was consistently less than 150 K.U. Histopathologic examination of the liver showedsubmassive hepatic necrosis without significant inflammation accompanied by marked fibrosis. Most hepatocytes showed strong nuclear expression ofHBcantigen by immunohistochemicalstaining and electron microscopy revealed numerous intranuclear core-like particles. Hepatitis B virus infection in immunosuppressed individuals occasionally insidiously progresses, resulting in liver failure. The clinical course of such patients thus merits close scrutiny. (Internal Medicine 32: 547-551, 1993) 
Introduction
Acute hepatitis B is generally a self-limiting disease. Disease activity completely subsides in most adult patients within 2 to 3 months of onset due to elimination of the virus. Persistent infection is observed less frequently.
In patients who undergo renal transplantation, the virus tends to proliferate due to immunosuppressionand there is a greater risk of becoming infected due to hemodialysis, surgery, orblood transfusion. Ofhemodialysis patients, 4.5 to 14.9% are positive for HBs Agand approximately half become chronic carriers. Viral infection thus plays a major role in the development of liver disease after renal transplantation (1, 2) . In addition, viral hepatopathy developing during immunosuppression after organ transplantation may be severe (3, 4) . Nakashima et al have reported an HBVcarrier who developed fulminant hepatitis after renal transplantation (2) . Recently several reports have described liver failure from recurrent hepatitis B virus (HBV)infection and death in patients undergoing orthotopic liver transplantation for HBV-related chronic liver disease (5) (6) (7) (8) . Weherein report a patient whodeveloped hepatitis B virus (HBV) infection and eventually succumbed while receiving prednisolone (PSL) and cyclosporine A (CsA) after renal transplantation.
Case Report
A 47-year-old man with nephrotic syndrome (focal glomerulosclerosis) began hemodialysis in October 1988 and underwent cadaveric renal transplantation in December1 989. Liver function tests at the time of surgery showedno abnormalities, and HBsantigen (HBs Ag) was negative in both donor and recipient. While the patient was receiving 10 mg/day of PSL and 60 to 120 mg/day ofCsA, general malaise, slightly elevated serum alanine aminotransferase (ALT) and total bilirubin (T.B il) , and decreased total cholesterol (T.Choi) were noted in July 1990 ( Fig. 1) served. Ascites was present and neither the liver nor spleen was palpable. The transplanted kidney was palpable in the right lower abdomen. Laboratory findings are shown in Table 1 .
Leukocytosis and thrombocytopenia were observed in the peripheral blood. Biochemical examination showed increased serum transaminases and T.Bil and decreased choline esterase (Ch-E) and T.Choi while the prothrombin time (PT) and hepaplastin test (HPT), were prolonged, suggesting a marked decrease in liver synthetic function. The serum oc-fetoprotein (AFP) level was 14 ng/mL (normalrange: 20 ng/mL or less) and the concentration of human hepatocyte growth factor (hHGF) was 1.0 ng/mL (normal range: 0.3 ng/mL or less, by ELISA). The thrombin antithrombin-III complex (TAT) and plasmin a2-plasmin inhibitor complex (PIC) concentrations were nearly normal, and there was no evidence for hyper-coagulation or enhanced fibrinolysis suggestive of DIC. Serologic assays showed HBs Ag and HBeAg positivity and high titers of antiHBc IgM antibody (IgM anti-HBc) and HBV-DNA-p. The RNA or DNA assays (PCR) for hepatitis C virus, cytomegalovirus, herpes simplex virus, and Epstein Barr virus were all negative. Antibody directed against the hepatitis D virus, HTLV-I, and HTLV-III were all negative.
After admission, 100 mL/day of intravenous glycyrrhizin was given in addition to PSL at 35 mg/day that had been initiated by the previous physician. However, the dose of PSL was tapered to 25 mg/day because of kmarked decrease in glucose tolerance and the development of gingival and urinary tract infections. During the subsequent clinical course, the HBe Ag remained positive, the HBe antibody remained negative, and the anti-HBc IgM remained high while the DNA-pdecreased from 8,033 to 2,1 19 cpm. Humanserum albumin and antithrombin III (AT III) preparations were administered as needed to maintain appropriate serum levels. Late in January, jaundice deepened and the PT and HPT became more prolonged. Despite supportive therapy such as glucagon-insulin infusion, administration of a protease inhibitor, branched chain amino acid infusion, administration of prostaglandin Eb hemodialysis, and plasma exchange, the patient died of liver and renal failure on February 26, 1991 , 7 months after the onset of hepatitis B. During hospitalization in our department, the AFP level remained low, and the hHGFincreased slightly (Fig.   2 ). 
Autopsy Findings
The liver weighed 820 g, showing marked atrophy. The surface was covered with light yellow nodules. Liver histology showed extensive hepatocyte necrosis and marked pseudo bile duct proliferation. In the portal areas, there was inflammatory cell infiltration consisting primarily oflymphocytes and marked fibrosis concentrated in the portal areas and extending to the interlobular areas (Fig. 3) . HBc antigen (HBc Ag) staining by the PAPmethod showed a strongly positive reaction in the nucleus of most hepatocytes but not in the cytoplasm (Fig. 4) . Electron microscopy revealed numerousintranuclear core-like particles (25 to 30 nm in diameter) in most hepatocytes ( 
Discussion
The characteristic laboratory findings in our patient were that IgM anti-HBc antibody and HBV-DNA-p were always positive and that the serum transaminase level remained low until liver failure occurred (Fig. 1) . The HBs Ag was negative at the time of renal transplantation and an abnormal serum ALT (7), and Benner et al (8) have reported similar novel lesions termed "fibrosing cholestatic hepatitis" or "fibrosing cytolytic hepatitis", respectively. The present case showedhistologic findings closely resembling the features reported by Davies and Benner. Immunosuppression may actually facilitate the development of"fibrosing cholestatic hepatitis" associated with hepatitis B infection.
In hepatitis B, cellular immunity directed against virusinfected cells is considered to play a primary role in hepatocyte damage. This immuneresponse would be expected to decrease with marked immunosuppression. In our patient, the degree of inflammatory cell infiltration was minimal (Fig. 3 ) and the increase in the serum transaminase level was slight. Thus, progression of hepatitis cannot be fully explained by cellular immunity as mediated by cytotoxic T cells alone. One cause of a fatal outcome in hepatitis can be failure of Fatal HBVInfection after Renal Tx liver regeneration. Serum AFPand hHGFare indices of liver regeneration and disease activity in severe hepatitis (9) . In our patient, the serum AFPlevel was decreased and the serum hHGFlevel was increased, suggesting that hepatitis progressed and liver regeneration did not occur (Fig. 2) . HBcAg-positive nuclei were observed throughout the hepatic lobules in the liver tissue, and electron microscopy showednumerousintranuclear HBV-coreparticles comparedwith the typical case of acute hepatitis B virus infection (Figs. 4, 5) . The presence of such inclusions suggests active virus proliferation in the nucleus. The relationship between virus proliferation and cell regeneration is unknown. However, the existence of a number of intranuclear HBV-coreparticles may have somenegative effect on hepatocyte division and metabolism required for cellular proliferation. Therefore immunosuppression might exacerbate hepatitis not only because ofhepatocyte damage through cellular immunity but also through other mechanisms such as regeneration failure. Direct HBV-induced hepatocyte injury has been reported in transgenic mice (10) , and a point mutation in the pre-C area has been reported to be implicated in fulminant hepatitis type B ( 1 1). The association between HBVproliferation or mutant hepatitis B virus and severe hepatic damagedue to immunosuppression should be also considered. Standard therapy for severe hepatitis was followed for our patient but without response. The immunosuppressed state after organ transplantation sometimes causes HBVproliferation and the progression of hepatitis, complicating therapy. Progression of hepatitis has been reported not only in patients with primary HBVinfection but also in HBVcarriers who undergo transplantation (2, 5, 6) . Suchcases are expected to increase in numberin the future as more organ transplants are performed. Further studies are needed on the mechanismof hepatitis progression, prevention of infection in transplant patients by HBVvaccine (12) , and newtreatment methodsusing interferon or high-titer y-globulin preparations (13, 14) . In conclusion, hepatitis B in immunosuppressed patients sometimes progresses insidiously and becomessevere. Consideration should be given to the possibility of HBVinfection at the time of organ transplantation and the dosage of immunosuppressants should be balanced very carefully based on the clinical course, complications, and the possibility of rejection.
